Investing.com - Financial Markets Worldwide

Smith & Nephew stock reaches 52-week high at 37.66 USD

Published 04/09/2025, 14:34
Smith & Nephew stock reaches 52-week high at 37.66 USD
SNN
1.50%

Smith & Nephew SNATS Inc. (SNN) stock has achieved a significant milestone by reaching a 52-week high of 37.66 USD. This marks a notable point for the medical technology company, reflecting a strong performance over the past year. The stock’s impressive 1-year change of 19.6% underscores the company’s growth and resilience in the market. Investors have shown confidence in Smith & Nephew’s strategic initiatives and product offerings, contributing to the stock’s upward trajectory and its new 52-week high.

In other recent news, Smith & Nephew has made notable appointments to its board. The company announced the appointment of Dr. Garheng Kong as an independent non-executive director and member of the Audit Committee, effective September 1, 2025. Dr. Kong brings a wealth of experience, currently serving as managing partner and co-founder of HealthQuest Capital, and holding positions at several other healthcare firms. Additionally, Smith & Nephew appointed David King as an independent non-executive director, effective July 1, 2025. King will also serve on the Compliance & Culture and Remuneration Committees, leveraging his extensive experience, including his previous role as CEO of Laboratory Corporation of America (LabCorp).

Smith & Nephew has also scheduled the release of its second quarter and half-year financial results for 2025. The company plans to publish these results on August 5, 2025, and will hold a conference call for financial analysts on the same day. This follows the company’s reported annual sales of $5.8 billion in 2024. These developments reflect ongoing strategic moves within Smith & Nephew as it continues to navigate the medical technology sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.